Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)
Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)
A phase 4 study to evaluate efficacy and safety of MUCOLASE tablet (streptokinase •
 streptodornase)
Double-blind, randomized, placebo controlled, multicenter, phase 4 clinical trial to assess
 the efficacy and safety of MUCOLASE tablet (streptokinase • streptodornase) in patients with
 acute upper respiratory infection or acute bronchitis
Inclusion Criteria:

 -  19≤ age

 -  Patients with acute upper respiratory infection or acute bronchitis

 -  Patients with cough and phlegm within 48 hrs as of Visit 1

 -  Patients understood the consents and purpose of this trial and signed consent form

 Exclusion Criteria:

 -  Patients with high fever (≥39℃)

 -  Patients with severe respiratory diseases (ex) bronchial asthma, pneumonia, pulmonary
 tuberculosis, bronchiectasis, mucus sticking, chronic obstructive pulmonary disease
 (COPD), etc.

 -  Patients with a history of hypersensitivity to drug

 -  Patients with abnormal blood coagulation

 -  Patients with thrombocytopenia

 -  Patients with uncontrolled hypertension

 -  Patients with a severe liver disorder(AST or ALT level exceeds 2 times more than
 normal upper range)

 -  Patients woth a clinically significant renal failure(MDRD eGFP < 60 mL/min/1.73m2)